FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancerThe Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including Share XScotland backs Merck/Pfizer’s Bavencio combo for kidney cancerhttps://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/
FDA fast-tracks Leap’s gastric cancer immunotherapyLeap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric Share XFDA fast-tracks Leap’s gastric cancer immunotherapyhttps://pharmaphorum.com/news/fda-fast-tracks-leaps-gastric-cancer-immunotherapy/
FDA’s review date for BMS’ ide-cel sneaks under the CVR wireThe FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, Share XFDA’s review date for BMS’ ide-cel sneaks under the CVR wirehttps://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/
AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drugAbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record Share XAbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drughttps://pharmaphorum.com/news/abbvie-signs-2-9bn-deal-with-i-mab-for-dont-eat-me-cancer-drug/
BMS swoops on Forbius, snaring another immuno-oncology playerWith the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development Share XBMS swoops on Forbius, snaring another immuno-oncology playerhttps://pharmaphorum.com/news/bms-swoops-on-forbius-snaring-another-immuno-oncology-player/
Blow for Novartis as PD-1 drug spartalizumab flunks trialNovartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed Share XBlow for Novartis as PD-1 drug spartalizumab flunks trialhttps://pharmaphorum.com/news/blow-for-novartis-as-pd-1-drug-spartalizumab-flunks-trial/
Latecomer Lilly throws cash at Innovent PD-1 partnershipEli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights Share XLatecomer Lilly throws cash at Innovent PD-1 partnershiphttps://pharmaphorum.com/news/latecomer-lilly-throws-cash-at-innovent-pd-1-partnership/
BMS’ Opdivo aces trial in asbestos-linked lung cancerBristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, Share XBMS’ Opdivo aces trial in asbestos-linked lung cancerhttps://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/
